Compare Inovio Pharmaceuticals Inc (INO) vs Prospect Capital Corporation (PSEC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs Prospect Capital Corporation — how do they compare? Inovio Pharmaceuticals Inc trades at $1.09 (market cap $89.27M), while Prospect Capital Corporation trades at $2.19 (market cap $1.12B). The key difference: Prospect Capital Corporation is far larger — about 12.5× Inovio Pharmaceuticals Inc's market cap, and Prospect Capital Corporation pays a 22.42% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| INO | PSEC | |
|---|---|---|
Market Cap | $89.27M | $1.12B |
Sector | Health | Financials |
52-Week High | $2.87 | $3.47 |
52-Week Low | $1.05 | $2.15 |
Enterprise Value | $60.28M | — |
Dividend Yield | — | 22.42% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INO trades at $1.07, down 4.46% today, reflecting persistent bearish technical signals. The company shows minimal revenue of $65.34K (2025) with a net loss of $84.95M, resulting in a negative net margin of 130,000%. Despite beating recent EPS estimates, cash flow remains negative. Key near-term catalyst is the FDA's PDUFA decision on INO-3107 by October 30, 2026.
Outlook hinges on regulatory success for INO-3107; approval could drive significant upside, but failure poses substantial risk. High cash burn and lack of profitability underscore speculative nature. Analyst consensus is cautiously optimistic with 53% buy ratings, yet financial health remains precarious without near-term revenue growth.
PSEC trades at $2.235, down 0.67% on the day, with a bearish technical signal and neutral oscillators. The stock shows a deeply discounted P/B ratio of 0.38 but alarming fundamentals, including a negative revenue of -$407M and a net income margin of -495.94% for 2025. Recent quarterly EPS has consistently beaten estimates, and the company maintains regular dividend payments. Analyst consensus is mixed, with 25% buy ratings but a majority hold recommendation.
The outlook for PSEC is highly speculative. The extreme discount to book value and high dividend yield present a potential value opportunity, but this is overshadowed by severe profitability issues and negative cash flow. Investment carries significant risk due to the company's inconsistent revenue history and bearish market sentiment, requiring careful consideration of the underlying asset quality.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About Prospect Capital Corporation
Prospect Capital Corp is a closed-end investment company based in the United States. Its investment objective is to generate both current income and long-term capital appreciation through debt and equity investments. The company invests primarily in senior and subordinated debt and equity of private companies for acquisitions, divestitures, growth, development, recapitalizations, and other purposes. It makes investments, including lending in private equity, sponsored transactions, directly to companies, investments in structured credit, real estate, and syndicated debt.
Read more on PSEC →
